Lu Xing, Guo Xiang, Hong Ming-Huang, Chen Qiu-Yan, Zeng Qi, Xiang Yan-Qun
Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China.
Chin J Cancer. 2010 Feb;29(2):140-4. doi: 10.5732/cjc.009.10433.
The platinum-based chemotherapy combined with 5-fluorouracil (5-FU) is most frequently used for nasopharyngeal carcinoma (NPC), but the efficacy has been maintained at 50%-60%. Docetaxel is an effective drug for head and neck tumors, its administration is simple, and the administration time is short. This study was to compare the short-term efficacy and toxicity between TC regimen (inductive chemotherapy with docetaxol plus carboplatin) and FC regimen (5-FU plus carboplatin) in local advanced NPC so as to provide a new chemotherapeutic regimen for NPC.
Fifty-eight local advanced NPC patients without previous treatment in Sun Yat-sen University Cancer Center were randomly assigned to receive either TC or FC regimen inductive chemotherapy, followed by concurrent chemoradiotherapy with two cycles of carboplatin (AUC=6) plus radiotherapy of 60-78 Gy to the nasopharynx and 60-70 Gy to the neck. The short-term efficacy and adverse events were observed.
More chemotherapy cycles were finished in TC group than in FC group (3.31 vs. 2.83, P = 0.043). There was no significant difference in short-term efficacy and 1-year survival rate between the two groups (P > 0.05). More grades 3-4 neutropenia appeared in TC group than in FC group (72.4% vs. 37.9%, P < 0.05) , whereas less thrombocytopenia and emesis occurred in TC than in FC group (P = 0.013 and 0.018, respectively).
The short-term efficacy of TC regimen in local advanced NPC is similar to that of FC regimen with tolerable adverse events. But the long-term outcomes and toxicities need to be further investigated.
铂类化疗联合5-氟尿嘧啶(5-FU)是鼻咽癌(NPC)最常用的治疗方案,但疗效一直维持在50%-60%。多西他赛是治疗头颈部肿瘤的有效药物,给药简便,给药时间短。本研究旨在比较多西他赛联合卡铂(TC方案)与5-FU联合卡铂(FC方案)诱导化疗局部晚期鼻咽癌的近期疗效及毒性,为鼻咽癌提供新的化疗方案。
中山大学肿瘤防治中心58例未经治疗的局部晚期鼻咽癌患者随机分为两组,分别接受TC或FC方案诱导化疗,随后进行同步放化疗,给予两个周期的卡铂(AUC=6),鼻咽部放疗剂量为60-78 Gy,颈部放疗剂量为60-70 Gy。观察近期疗效及不良反应。
TC组完成的化疗周期数多于FC组(3.31比2.83,P = 0.043)。两组近期疗效及1年生存率差异无统计学意义(P > 0.05)。TC组3-4级中性粒细胞减少发生率高于FC组(72.4%比37.9%,P < 0.05),而TC组血小板减少和呕吐发生率低于FC组(分别为P = 0.013和0.018)。
TC方案治疗局部晚期鼻咽癌的近期疗效与FC方案相似,不良反应可耐受。但长期疗效和毒性仍需进一步研究。